Frontline Gastroenterol
An oral Mazdutide or Retatrutide formulation would dramatically expand potential market reach
Exercise Daily exercise can amplify peptide therapys effect
If the compounded drug is not made properly, it can cause serious side effects
Contrastingly, GLP1 antagonist sales in 2023 showcase a more diversified landscape, with therapeutics such as Ozempic, Trulicity, and Mounjaro driving 71 per cent of the sales. Looking ahead, the GLP1 agonist market is poised for robust growth, anticipating a 19.2 per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029
In addition to its classic roles in the treatment of methemoglobinemia, distributive shock, and as a surgical dye, recent research has demonstrated potent anti-aging and neuroprotective properties